Drug Trial Radar · NCT04816604
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
74
Actual
Start
Apr 5, 2021
Primary completion
Sep 9, 2026
Study completion Sep 9, 2026
Sponsor
- Lead sponsor
- Gossamer Bio USA, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Conditions
- Pulmonary Arterial Hypertension
Interventions
GB002 (seralutinib)Drug
Capsule containing GB002 (seralutinib)
Generic Dry Powder InhalerDevice
Generic dry powder inhaler for GB002 (seralutinib) delivery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse EventsTime frame: From first dose of study drug up to 80 months or availability of commercial product
Locations
28 sites in 7 countries. Site status is shown where the registry gives one.
University of California, Davis Medical Center
Sacramento, California
Medical Corporation
Santa Barbara, California
Mayo Clinic
Jacksonville, Florida
Cleveland Clinic Florida
Weston, Florida
University of Kansas Medical Center
Kansas City, Kansas
Norton Pulmonary Specialists
Louisville, Kentucky
Tufts Medical Center
Boston, Massachusetts
University of Nebraska Medical Center
Omaha, Nebraska
NYU Langone Health
New York, New York
New York Presbyterian Hospital - Weill Cornell Medicine
New York, New York
University of Rochester Medical Center
Rochester, New York
The Ohio State University Wexner Medical Center
Columbus, Ohio
INTEGRIS Baptist Medical Center, Inc.
Oklahoma City, Oklahoma
Houston Methodist Hospital
Houston, Texas
University of Utah Health
Salt Lake City, Utah
Royal Hobart Hospital
Hobart, Tasmania, Australia
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
Všeobecná fakultní nemocnice v Praze
Prague, Czechia
AP-HP Hôpital de Bicêtre
Le Kremlin-Bicêtre, France
DRK Kliniken Berlin
Berlin, Germany
Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik IV und V
Giessen, Germany
Klinik für Pneumologie, Klinisches Studienzentrum Medizinische Hochschule
Hanover, Germany
Thoraxklinik-Heidelberg gGmbH
Heidelberg, Germany
Klinik und Poliklinik f. Innere Medizin II Universitätsklinikum Regensburg
Regensburg, Germany
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Royal Papworth Hospital NHS Foundation Trust
Cambridge, United Kingdom
Imperial College Healthcare NHS Trust - Hammersmith Medicines Research Limited
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.